CD106 Identifies a Subpopulation of Mesenchymal Stem Cells with Unique Immunomodulatory Properties

Zhou Xin Yang1,9, Zhi-Bo Han1,3,9, Yue Ru Ji1, You Wei Wang1,2, Lu Liang2,3, Ying Chi1, Shao Guang Yang1, Li Na Li4, Wei Feng Luo4, Jian Ping Li1, Dan Dan Chen1, Wen Jing Du1, Xiao Cang Cao5, Guang Sheng Zhuo3, Tao Wang3, Zhong Chao Han1,2,3

Abstract

Mesenchymal stem cells (MSCs) reside in almost all of the body tissues, where they undergo self-renewal and multi-lineage differentiation. MSCs derived from different tissues share many similarities but also show some differences in term of biological properties. We aim to search for significant differences among various sources of MSCs and to explore their implications in physiopathology and clinical translation. We compared the phenotype and biological properties among different MSCs isolated from human term placent al chorionic villi (CV), umbilical cord (UC), adult bone marrow (BM) and adipose (AD). We found that CD106 (VCAM-1) was expressed highest on the CV-MSCs, moderately on BM-MSCs, lightly on UC-MSCs and absent on AD-MSCs. CV-MSCs also showed unique immune-associated gene expression and immunomodulation. We thus separated CD106+ cells and CD106- cells from CV-MSCs and compared their biological activities. Both two subpopulations were capable of osteogenic and adipogenic differentiation while CD106+ CV-MSCs were more effective to modulate T helper subsets but possessed decreased colony formation capacity. In addition, CD106+ CV-MSCs expressed more cytokines than CD106- CV-MSCs. These data demonstrate that CD106 identifies a subpopulation of CV-MSCs with unique immunoregulatory activity and reveal a previously unrecognized mechanism underlying immunomodulation of MSCs.

Introduction

In recent years, mesenchymal stem cells have attracted significant attention from basic and clinical investigators for their usefulness in the treatment of immune disorders, such as graft-versus-host disease (GVHD) and autoimmune diseases [1,2]. MSCs constitute a specialized tissue microenvironment or niche, where they undergo self-renewal and multi-lineage differentiation [3]. MSCs were first isolated from bone marrow [4], and subsequently found in nearly every tissue attempted so far, including adipose [5], umbilical cord [7] and cord blood [8].

A number of studies have shown that MSCs derived from different tissues share many similarities but also exhibit some differences. Using identical culture conditions, major differences in term of differentiation potentials as well as biological functions [7,9]. Placental and umbilical cord derived MSCs are more primitive because they share more common genes with embryonic stem cells (ESCs) [10]. UC-MSCs express genes enriched in vascular endothelial growth factor and PI3K-NFκB canonical pathways, whereas BM-MSCs express genes involved in antigen presentation and chemokine/ cytokine pathways. UC-MSCs thus constitute a promising option for angiogenesis, whereas BM-MSCs for bone remodeling [11]. Furthermore, it has been found that the migration of placental and BM-MSCs was found to be 5.9 and 3.2 folds higher than that of UC-MSCs, respectively [12]. BM-MSCs show a stronger stimulating effect on megakaryocyte progenitor expansion than those from UC-MSCs [13] and display a better chondrogenic differentiation compared with other sources of MSCs [14]. In addition, the cytokine profiling is different based on the sources of MSCs [15]. MSCs from different tissues display different potential in proliferation, differentiation, immunomodulation and hematopoiesis supportive abilities, and these differences indicate a demand for effective preparation protocols tailored to each type of MSCs against different diseases [16].

One of the important biological functions of MSCs is the immunomodulation. MSCs can alter the function of T cells, B cells, dendritic cells and NK cells, and thereby exhibit potent immunosuppressive activity [17]. Generally, MSCs display their
immunomodulatory activities through direct cell-cell contact and/or secretion of soluble factors [17]. Cell – cell adhesion mediated by CD106 is known to be critical for T cell activation and leukocyte recruitment to the inflammation site and, therefore, plays an important role in evoking effective immune responses. CD106 is also reported as one of components of neural stem cells [18]. Moreover, CD106 is critical for MSCs-mediated immunosuppression [19] and for the binding of hematopoietic progenitor cells [20].

In the present study, we report a positive correlation between CD106 expression and immunosuppressive effect of CV-MSCs. We also show that TNF-α and IL-1β are required for CD106+MSCs expansion. Our data suggest that CD106 could be used as a biomarker for a subpopulation of CV-MSCs with unique immunosuppressive activity.

Materials and Methods

Generation of human BM-MSCs, AD-MSCs, UC-MSCs and CV-MSCs

This study was approved by the Institutional Review Board of Chinese Academy of Medical Sciences and Peking Union Medical College. Bone marrow, adipose tissues, term placenta, umbilical cords, peripheral blood and cord blood were obtained from donors with written informed consent.

Table 1. Primers for real time reverse transcription – polymerase chain reaction.

| Primers | BM-MSCs | AD-MSCs | UC-MSCs | CV-MSCs |
|---------|---------|---------|---------|---------|
| Human β-actin forward: | 5′-CACGAGGAGAGACCGATCC-3′ | | | |
| Human β-actin reverse: | 5′-CTGGGATGTTGAAAGCTTT-3′ | | | |
| Human VCA-1 forward: | 5′-GGGAGATGACCAAAACACT-3′ | | | |
| Human VCA-1 reverse: | 5′-AGCTGTAATGCTGAGAGAC-3′ | | | |
| Human COX-2 forward: | 5′-AGCTGGTATGATCTGGGAGAC-3′ | | | |
| Human COX-2 reverse: | 5′-AGCTGGTATGATCTGGGAGAC-3′ | | | |
| Human IDO1 forward: | 5′-AGCAGGCTGGAGAGACTG-3′ | | | |
| Human IDO1 reverse: | 5′-AGCAGGCTGGAGAGACTG-3′ | | | |
| Human TGβ-1 forward: | 5′-ACTGCAAGTGGAACATCAGG-3′ | | | |
| Human TGβ-1 reverse: | 5′-TGGGAAATCCAACTCGGAC-3′ | | | |
| Human IL-1α forward: | 5′-CGGAATGACTGAGAGAC-3′ | | | |
| Human IL-1α reverse: | 5′-CGGAATGACTGAGAGAC-3′ | | | |
| Human IL-1β forward: | 5′-AGCTGAAATGACTCAGGAC-3′ | | | |
| Human IL-1β reverse: | 5′-AGCTGAAATGACTCAGGAC-3′ | | | |
| Human IL-6 forward: | 5′-CCACAGACAGCAAGCTAC-3′ | | | |
| Human IL-6 reverse: | 5′-CCACAGACAGCAAGCTAC-3′ | | | |
| Human IL-8 forward: | 5′-TTGGCAATGCTTCTGATT-3′ | | | |
| Human IL-8 reverse: | 5′-TTGGCAATGCTTCTGATT-3′ | | | |
| Human IFN-γ forward: | 5′-GTGGTGAAGACCAACTAGG-3′ | | | |
| Human IFN-γ reverse: | 5′-GTGGTGAAGACCAACTAGG-3′ | | | |
| Human TNF-α forward: | 5′-GCAGTGAAAGCTTGAGTG-3′ | | | |
| Human TNF-α reverse: | 5′-GCAGTGAAAGCTTGAGTG-3′ | | | |
| Human T-bet forward: | 5′-GGCTGACAGCTGAAAGAT-3′ | | | |
| Human T-bet reverse: | 5′-GGCTGACAGCTGAAAGAT-3′ | | | |
| Human HLA-G forward: | 5′-GAGTGTGGACCATCAAGGAAG-3′ | | | |
| Human HLA-G reverse: | 5′-GAGTGTGGACCATCAAGGAAG-3′ | | | |

Table 2. Phenotype of BM-MSCs, AD-MSCs, UC-MSCs and CV-MSCs.

| Markers | BM-MSCs | AD-MSCs | UC-MSCs | CV-MSCs |
|---------|---------|---------|---------|---------|
| CD11b | – | – | – | – |
| CD19 | – | – | – | – |
| CD29 | +++ | +++ | +++ | +++ |
| CD31 | – | – | – | – |
| CD34 | – | – | – | – |
| CD44 | +++ | +++ | +++ | +++ |
| CD45 | – | – | – | – |
| CD73 | +++ | +++ | +++ | +++ |
| CD90 | +++ | +++ | +++ | +++ |
| CD105 | +++ | +++ | +++ | +++ |
| CD106 | + or ++ | – | + | +++ |
| HLA-DR | – | – | – | – |
| Nestin | +++ | +++ | +++ | +++ |
| SOX2 | ++ | +++ | +++ | +++ |

The isolation and expansion of MSCs were performed as described previously [7]. The basic culture medium for isolation of MSCs was the complete DF-12 medium (Gibco) containing 10% fetal calf serum (FCS) (HyClone), 2 mM glutamine, 100U/ml penicillin-streptomycin, and 10 ng/ml epidermal growth factor (EGF; Peprotech). Samples from 3 donors each were used to generate human BM-MSCs, AD-MSCs, UC-MSCs and CV-MSCs.

Flow cytometric analysis

Phenotype of MSCs was analyzed using the following antibodies: FITC-conjugated-CD11b, CD31 and CD34; PE-conjugated-CD3, CD4, CD8, CD45, CD54, CD73, CD90, CD105, CD106 and HLA-DR. Non-specific isotype-matched antibodies served as controls. For Tregs, CD4+ T cells were labeled with PE-conjugated CD4, FITC-conjugated CD25, and then labeled PE-Cy5-conjugated Foxp3 by using Foxp3 Staining Buffer Set (eBioscience). All of the antibodies were purchased from BD Pharmingen. Cells were analyzed by flow cytometry in a FACS Calibur, using the CellQuest software (Becton Dickinson).

Separation of CD106+CV-MSCs and CD106−CV-MSCs

Subpopulations of MSCs were separated using EasySep® PE Positive Selection Kit (StemCell Technologies). MSCs were detached by 0.025% trypsin and labeled with PE-anti CD106 antibody, and CD106+ and CD106− cells were separated according to manufacturer’s instructions. In some cases, flow sorting was used. MSCs were labeled with PE-anti CD106 antibody, the positive and negative cells were separated using BD Influx (Becton Dickinson). For both of the methods, the purity of isolated cells was more than 90%.

Osteogenic and adipogenic differentiation

Osteogenic and adipogenic differentiation was carried out as described previously [7]. Briefly, cells were plated in 24-well plates at a density of 3000 cells/cm². The medium was changed with...
specific induction medium 24 hours later. For osteogenic induction, STEMPRO Osteogenesis Differentiation Kit (GIBCO) was used. For adipogenic induction, medium consisted of DMEM supplemented with 10% FBS, 1 μmol/L dexamethasone, 5 μg/mL insulin, 0.5 mmol/L isobutylmethylxanthine (IBMX), and 60 μmol/L indomethacin was used. Reagents for adipogenic induction were purchased from Sigma. After 3 weeks of induction, the cells were stained using alizarin red S or oil red O solution.

Colony forming unit-fibroblast assay
For fibroblastic-like colony formation assay, 3 cells/cm² of CD106^+ or CD106^- CV-MSCs were seeded in T75 culture flask. The cell media were changed every 7 days. The culture was ended at day 14, and the adherent cells were washed twice with phosphate-buffered saline, and stained with 0.2% crystal violet in 80% methanol for 20 min at room temperature. Then the cells were washed again and the colonies were counted.

Isolation of human peripheral blood mononuclear cells (hPBMCs) and human cord blood mononuclear cells (hCBMCs) CD4^+ T cells
Human PBMCs and CBMCs were isolated by Ficoll-Paque (Axis-Shield) density gradient centrifugation from blood of health volunteer donors. CD4^+ T cells were purified using relevant magnetic MicroBead kits (Miltenyi Biotec) according to the manufacturer's instructions. The purity of CD4^+ T cells was more than 95%.

Co-culture of immune cells and MSCs
Cells were cultured in complete 1640 medium (Gibco) containing 10% fetal bovine serum (FBS) (FBS- NZ ORIGIN), 2 mM glutamine, 100 U/mL penicillin and streptomycin, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate. MSCs (30 Gy irradiated) were plated in 96-well flat-bottom plate and allowed to adhere for 18 h at 37°C, and then 10⁵ PBMCs or CD4^+T cells were added in. Human PBMCs were stimulated by phytohemagglutinin (PHA, Sigma, 10 μg/ml) and CD4^+T cells were stimulated by PHA (10 μg/ml) and IL-2 (peprotech, 10 ng/ml) for 72 hours. For the regulatory T cells (Tregs), CD4^+ T cells were stimulated with IL-2 (10 ng/ml) for 5 days. Cells were isolated and labeled with CD4, CD25 and Foxp3.

Affymetric Genechip assay
2 x 10⁶ of CD106^+ and CD106^- CV-MSCs was collected and resuspended in Trizol (Invitrogen). The samples were stored in −80°C for genechip assay. The Microarray was done by CapitalBio Corporation. Data was analyzed using mas3.0 molecule annotation system.

RNA isolation, reverse transcription and real time PCR
Total RNA was extracted by E.Z.N.A. Total RNA Kit I (OMEGA), and cDNA synthesis with MLV RT kit (Invitrogen) for 50 min at 37°C in the presence of oligo-dT primer. Real-time polymerase chain reaction analyses were performed by Platinum® SYBR® Green qPCR SuperMix-UDG w/ROX (invitrogen) on an Applied Biosystems 7300 Real-Time PCR System. Primers used were listed in Table 1.

In vitro stimulation of MSCs
10⁵ cells/ml MSCs were seeded in to a 6 well plate in 2 ml for 24 hours, and then treated with IFN-γ (30 ng/ml), IL-1β (10 ng/ml) or TNF-α (30 ng/ml) for 24 hours. All of the pro-inflammatory cytokines were purchased from peprotech.
ELISA

Cell-free supernatants were collected and kept in refrigerator at −80°C. PGE₂ ELISA kit was purchased from Cayman Chemicals. IFN-γ was tested using the kit from ebioscience. All of the ELISA assay kits were used following the supplier’s instruction.

Statistical analysis

The data were analyzed for statistic significance using the GraphPad Prism software. Data are presented as mean ± SEM. Student’s unpaired t-test and ANOVA with bonferroni post hoc test were used to determine significance, p < 0.05 was considered to be statistically significant.

Results

Placental chorionic villi MSCs highly express CD106

To determine most significant differences among MSCs of different origins, we first compared the phenotypes of MSCs isolated from human term placental CV, UC, adult BM and AD using identical methods. Each type of MSCs was tested for 3

Table 3. Differential pathways of CD106⁺ and CD106⁻ CV-MSCs.

| Pathway                                      | Count | q-Value     |
|----------------------------------------------|-------|-------------|
| Cytokine-cytokine receptor interaction       | 21    | 8.40E-15    |
| TGF-beta signaling pathway                   | 11    | 2.85E-10    |
| Cell adhesion molecules (CAMs)               | 12    | 1.88E-09    |
| MAPK signaling pathway                       | 15    | 8.17E-09    |
| Graft-versus-host disease                    | 5     | 4.30E-05    |
| Jak-STAT signaling pathway                   | 8     | 4.62E-05    |
| Chondroitin sulfate biosynthesis             | 4     | 5.91E-05    |
| O-Glycan biosynthesis                        | 4     | 2.11E-04    |
| Focal adhesion                               | 8     | 2.67E-04    |
| Type 1 diabetes mellitus                     | 4     | 6.58E-04    |
| Axon guidance                                | 6     | 7.13E-04    |
| ECM-receptor interaction                     | 5     | 7.41E-04    |
| Hematopoietic cell lineage                   | 5     | 8.33E-04    |
| Wnt signaling pathway                        | 6     | 0.001391    |
| Glycosphingolipid biosynthesis – lactoseries| 3     | 0.001572    |
| Complement and coagulation cascades          | 4     | 0.002474    |
| Melanoma                                     | 4     | 0.002728    |
| Calcium signaling pathway                    | 6     | 0.002957    |
| Bladder cancer                               | 3     | 0.00505     |
| Prostate cancer                              | 4     | 0.005125    |
| ABC transporters – General                   | 3     | 0.005554    |
| Regulation of actin cytoskeleton             | 6     | 0.00583     |
| Gap junction                                 | 4     | 0.00598     |
| Glycerolipid metabolism                      | 3     | 0.006415    |
| Toll-like receptor signaling pathway         | 4     | 0.007696    |

doi:10.1371/journal.pone.0059354.t003

Figure 2. Comparison of different gene expression in BM-MSCs, AD-MSCs, UC-MSCs and CV-MSCs. (A) BM-MSCs, AD-MSCs, UC-MSCs and CV-MSCs were co-cultured with PHA (10 μg/ml) stimulated PBMCs for 72 hours. 10⁵ PBMCs and 2×10⁴ MSCs were added to a well of 96 well plates. IFN-γ production of activated-PBMCs was evaluated by ELISA. Percentage change of IFN-γ was gained by direct comparison to the control (activated PBMCs alone). (B) UC-MSCs and CV-MSCs from the same individuals were co-cultured with PHA stimulated PBMCs for 72 hours. A corresponding set of MSCs was tested. IFN-γ concentration in culture medium was measured by ELISA. Percentage change of IFN-γ was gained by direct comparison to the control (activated PBMCs alone). The results are presented as mean ± SEM of single experiment, and the experiment have been performed at least in triplicate (*p<0.05), 3 donor samples were used. (C) Relative mRNA expression of COX-2, IL-1α, IL-1β, IL-6, IL-8 and TGF-β1 in BM-MSCs, AD-MSCs, UC-MSCs and CV-MSCs. Cells of passages 3 from 3 donors were used respectively. (D) RT-PCR array results of immune related genes in UC-MSCs and CV-MSCs (from the same individual). –ΔCt (cycle threshold) were compared and shown in a scatter plot. (E) PGE₂ concentration in culture medium of BM-MSCs, AD-MSCs, UC-MSCs and CV-MSCs after 72 hours culturing. The original seeding number is 10⁵/well of 6 well plates. Supernatant were obtained 72 hours later. Cells of passages 3 were used (from 3 donors) (**p<0.001).

doi:10.1371/journal.pone.0059354.g002

Figure 3. Isolation of CD106⁺ cells and CD106⁻ cells from CV-MSCs. Image for morphology and differentiation of MSCs were taken by OLYMPUS DP72. (A) Morphology of CD106⁺ and CD106⁻ cells from CV-MSCs. (B) Differentiation potential of CD106⁺ and CD106⁻ cells from CV-MSCs. Alizarin red S staining for osteogenic differentiation and oil red O staining for adipogenic differentiation. (C) Colony formation ability of CD106⁺ and CD106⁻ cells from CV-MSCs. The number of CFU-F was counted after 14 days culture (*p<0.05).

doi:10.1371/journal.pone.0059354.g003
donors. A series of cell markers were examined at passage 3 of in vitro cultivation, including CD11b, CD19, CD29, CD34, CD44, CD45, CD73, CD90, CD105, CD106, HLA-DR, Nestin and SOX2. All these four types of MSCs highly expressed embryonic stem cell markers Nestin and Sox2, as well as mesenchymal markers including CD29, CD44, CD73, CD90 and CD105 (Table 2). The most significant difference of their phenotypes was the CD106 expression, which was expressed highly on the CV-MSCs (68.26 ± 7.970%), moderately on BM-MSCs (15.85 ± 8.208%), lightly on UC-MSCs (4.067 ± 2.197%) and absent on AD-MSCs (Figure 1A, B).

Gene expression pattern of placental chorionic villi MSCs is unique

To determine if different origins of MSCs affect Th1 specific cytokine IFN-γ expression, we then compared levels of IFN-γ using ELISA. PBMCs secreted IFN-γ upon stimulation of PHA (10 μg/ml). All of these MSCs suppressed the expression of IFN-γ in hPBMCs in the presence of PHA (Figure 2A). To exclude the possibility that the differences among MSCs were due to individual differences, we tested the UC-MSCs and CV-MSCs obtained from the same fetus origin. Interestingly, CV-MSCs (19.99 ± 0.8328% compared with PHA-activated hPBMCs) showed a significantly increased inhibitory effect on IFN-γ production of the hPBMCs compared to UC-MSCs (48.74 ± 7.323% compared with PHA-activated hPBMCs) (Figure 2B), indicating that placenta CV contain a valuable source of MSCs with increased immunomodulatory activity.

To examine the mRNA expression of several immune factors in the four sources of MSCs, realtime PCR was performed. It is interesting to note that CV-MSCs expressed highest level of mRNA for COX-2 (Cyclooxygenase-2, inducible synthase for PGE2), IL-1α, IL-1β, IL-6 and IL-8. However, the expression of TGF-β1 was similar in each type of MSCs (Figure 2C, D). The expression of IDO1 mRNA was very low in all sources unless treated by pro-inflammatory cytokines like IFN-γ. Importantly, CV-MSCs showed strongest ability to secrete PGE2 among the four sources of MSCs (44.00 ± 8.814 ng/ml) (Figure 2E).

CD106+MSCs differ from CD106− MSCs in their colony formation and immunosuppressive capacities

CV-MSCs possess the strong immunomodulatory potential and express highly CD106. We thus hypothesized that CD106+CV-MSCs maybe a novel subpopulation specialized in immunosuppression. To test this hypothesis, the CD106+ cells and CD106− cells were therefore separated from CV-MSCs, either by MACS or SORTING. Both of CD106+ cells and CD106− cells showed typical MSCs morphology (Figure 3A) and osteogenic and adipogenic differentiation abilities (Figure 3B), conforming their identical multipotent stem cell potential. Interestingly, CD106+CV-MSCs possessed a five-fold decreased ability for colony formation than CD106−CV-MSCs (Figure 3C), suggesting that the CD106 may appear on the MSCs at late developmental stage.

We then compared the ability of CD106+CV-MSCs and CD106−CV-MSCs to inhibit the Th1 response by testing the
IFN-γ production. CD106⁺CV-MSCs or CD106⁻CV-MSCs did not induce IFN-γ secretion of PBMCs without stimulation. PBMCs secreted IFN-γ upon stimulation of PHA. The addition of CD106⁺CV-MSCs or CD106⁻CV-MSCs resulted in a significant reduction of IFN-γ secretion of PHA stimulated PBMCs, but their inhibitory degree was different. The CD106⁺CV-MSCs induced an almost complete inhibition of IFN-γ secretion whereas CD106⁻CV-MSCs induced only partial inhibition (Figure 4A). In addition, CD106⁺CV-MSCs suppress TNF-α production to a lower level than CD106⁻CV-MSCs (Figure 4A). Furthermore, determination of intracellular cytokine contents on the CD4⁺T cells of the co-cultures showed that both types of CV-MSCs decreased at different degree the expression of IFN-γ and TNF-α, although CD106⁺CV-MSCs were more effective (Figure 4B and
CD106+MSCs with Unique Immunomodulatory Properties

Figure 5. Gene expressions of CD106+ and CD106− CV-MSCs. (A) The gene expression profile of CD106+ and CD106− CV-MSCs were determined using Affymetrix oligoarrays and the scatter plot shows the gene expression level. Red plots indicate genes up regulated in CD106+ and green plots indicate genes up regulated in CD106− CV-MSCs. (B) Relative mRNA expressions of COX-2, IL-1α, IL-1β, IL-6 and IL-8 in CD106+ and CD106− CV-MSCs were determined by real-time PCR. (C) 104 of CD106+ or CD106− CV-MSCs were cultured for 72 hours and PGE2 concentration in supernatant was measured by ELISA. (D) CD106+ or CD106− CV-MSCs were cultured with IFN-γ for 24 hours and relative mRNA expressions of IDO1 were determined by real-time PCR. The results are presented as means ± SEM of three separate experiments.

doi:10.1371/journal.pone.0059354.g005

CD106+ CV-MSCs express higher levels of immunoregulatory factors than CD106− CV-MSCs

To explore the mechanism underlying increased immunosuppressive function of CD106+ CV-MSCs, we performed microarray to analyze the gene expression pattern of CD106+ CV-MSCs and CD106− CV-MSCs, and real-time PCR was performed to confirm the results from microarray analysis. The expression of adherence molecules and cytokines were different in CD106+ and CD106− CV-MSCs, indicating different functions for two kinds of MSCs. Notably, the gene expression profiles associated with immunoregulatory factors were different, indicating different functions of these two subpopulations (Table 3 and 4). CD106+CV-MSCs express higher levels of COX-2, IL-1α, IL-1β, IL-6 and IL-8 compared with CD106−CV-MSCs (Figure 5A and B). CD106+CV-MSCs showed an increased ability to secrete PGE2 compared to CD106−CV-MSCs (Figure 5C). To test the ability for another important immune modulator IDO1, IFN-γ was used to stimulate the MSCs. IFN-γ significantly up regulated the expression of IDO1 in 24 hours. CD106+ cells express higher level of IDO1 than CD106− cells in the presence of IFN-γ (Figure 5D). Together, CD106+CV-MSCs expressed higher level of immunomodulating factors compared with CD106− CV-MSCs.

CD106 expression on CV-MSCs is controllable in response to propagation and cytokine induction

To determine if the CD106 expression on CV-MSCs is tissue specific and stable during long-term cultivation, we cultured CV-MSCs under different condition. It was interesting to observe that the expression of CD106 decreased after passaging in basic culture media (Figure 6A). Accordingly, there was a reduction of mRNA expression of COX-2, IL-1α, IL-1β, IL-6 and IL-8 (Figure 6B) and a reduction of PGE2 production (Figure 6C).

We then wanted to know if CD106+ CV-MSCs could be induced to express CD106 and thereby increase their immunosuppressive ability. CD106+ CV-MSCs were treated with IFN-γ, TNF-α or IL-1β for 24 hours. The addition of pro-inflammatory cytokines resulted in an increased expression of COX-2, IL-1α, IL-1β, IL-6 and IL-8 in CD106+ CV-MSCs (Figure 7). IFN-γ apparently up regulated CD106+ and IL-6 expression, but failed in other genes. Together, these results indicate that the expression of CD106 on MSCs is variable, and suggest that TNF-α, IFN-γ, but not IFN-γ, may be important for generation of CD106+MSCs.

Discussion

In this study, using CD106 as a surface marker, we have successfully demonstrated a previously uncharacterized heterogeneity of MSCs isolated from chorionic villi. CD106+CV-MSCs possess high immunomodulation activity, whereas CD106− CV-MSCs possess high colony formation capacity. In addition, we provide several lines of evidence that the immunosuppressive activity of MSCs is highly related to their ability for the secretion of immunoregulatory cytokines and PGE2. In CD106+ cells, a list of genes was up regulated, including COX-2, IL-1α, IL-1β, IL-6...
and IL-8. The biological activity of CD106+ CV-MSCs was highly related to the stimulation of pro-inflammatory cytokines TNF-α and IL-1β.

To our knowledge, CD106 is a cytokine-inducible cell surface protein capable of mediating adhesion to leukocytes expressing alpha 4 integrins. CD106-deficient mouse embryos were not viable and exhibited either of two distinct phenotypes. Half of the embryos died before embryonic day 11.5 and exhibited severe defects in placental development. The remaining CD106-deficient embryos survived to embryonic day 11.5–12.5 and displayed several abnormalities in their hearts development [21]. The role of CD106 in embryonic development is very important for the formation of the umbilical cord and placenta [22].

Human placenta is an important organ to provide nutrition, gas exchange, waste removal, endocrine and immune support during fetus development. The chorionic villi constitute a part of the border between maternal and fetal blood providing exchange between maternal and fetal circulation. Recently, the placenta has been recognized as an immune organ, creating a fetomaternal immune-privileged environment enabling the survival of the semi-allogeneic fetus [23,24]. The underlying mechanism for the placental immune tolerance has been found to depend on

Figure 6. Gene expressions of CV-MSCs changed by passages. (A) CD106 expressions in CV-MSCs were detected by flow cytometry. Passages 3, 6, 9 were used. (B) Relative mRNA expressions of CD106, COX-2, IL-1α, IL-1β, IL-6 and IL-8 in CV-MSCs were determined by real-time PCR. Passage 3 and passage 9 were used. (C) 10^5 of CV-MSCs were cultured for 72 hours and PGE2 concentration in supernatant was measured by ELISA. Passage 3 and passage 9 were used. The results are presented as means ± SEM of three separate experiments.

doi:10.1371/journal.pone.0059354.g006
regulatory T cells [25], negative signals from the PD1-PDL1 costimulatory pathway [26], IL-17-producing T cells (Th17) [27] and FAS-Ligand [28]. Th1 immune response should be suppressed, in order to maintain the fetomaternal tolerance. Wegmann and colleagues first developed the concept that there is a shift from a T helper 1 response to a T helper 2 bias during pregnancy that functionally induces maternal tolerance and suppression [29]. Administration of the Th1 interleukin IFN-γ [30] leads to fetal loss and preterm labor in the mouse. However, little is known about the contribution of MSCs resided in placental chorionic villi to fetomaternal tolerance. We discovered that both of CD106\(^{+}\)CV-MSCs and CD106\(^{-}\)CV-MSCs could modulate the IFN-γ secretion, while CD106\(^{+}\)CV-MSCs were more effective. Surface molecules like CD106 and CD54 are considered to be important for immune modulation of MSCs [19]. Besides, soluble factors are also critical for immuno-suppression of MSCs. MSCs modulate the immune response via soluble factors such as PGE\(_2\) [10], IDO1 [31], transforming growth factor beta 1 (TGF-β1) [32], hepatocyte growth factor (HGF) [33], Interleukin 6 (IL-6) [34], HLA-G [35], Nitric oxide (NO) [36], and Galectin-1 [37]. COX-2 is critical for synthesis of inducible PGE2. In CD106\(^{+}\)cells, COX-2 was highly expressed, which indicated that CD106\(^{+}\)cells secrete high level of PGE2 mediating the immune modulation function of UC-MSCs [10]. IDO1 can be induced by IFN-γ [31] and CD106\(^{+}\)CV-MSCs express higher level of IDO1 than CD106\(^{-}\)CV-MSCs after stimulating with IFN-γ. PGE2 was reported to regulate IDO1 [38,39]. In our study we also observed that CD106\(^{+}\)cells are more effective to induce IDO1.

COX-2 expression in fetal membranes seems to be important for pregnancy, as multiple female reproductive failures were observed in COX-2 deficient mice [40]. COX-2 highly expressing CD106\(^{+}\)cells may have more functions but not only immune modulation. IL-1 is also critical for pregnancy. IL-1Ra prevents embryonic implantation by directly affecting the endometrial epithelium [41]. In addition, human placenta is a potent hematopoietic niche [42], the effect of CD106\(^{+}\)CV-MSCs on haemopoiesis and angiogenesis may be an interesting field for further study.

Pro-inflammatory cytokines like IFN-γ, IL-1β and TNF-α secreted by immune cells are critical to induce immunomodulatory ability of MSCs [43–46]. MSCs stimulated by pro-inflammatory cytokines were shown to be more effective to modulate the immune response in vitro [47] and in vivo [44]. CD106\(^{+}\)CV-MSCs showed similar gene expressions with CD106\(^{-}\)CV-MSCs after stimulating with IL-1β or TNF-α, but...
not IFN-γ. Interestingly, IL-1β and TNF-α have been shown to be important for reproductive [48,49], while IFN-γ is low at the maternal-fetal interface [29]. To maintain or induce CD106+CV-MSCs, stimulation in the microenvironments may be needed, and IL-1β or TNF-α might be candidate stimuli. Certainly other cytokine and cell-cell contact may also participate in the development of CV-MSCs.

In summary, this study reports for the first time that CD106 identifies a unique subpopulation of MSCs with powerful immunosuppressive activity, CD106+MSCs mainly reside in human term placenta, which may contribute to fetomaternal tolerance. Our future work will be best directed toward designing therapeutic strategies for the treatment and prevention of GVHD or other autoimmune disorders as well as early pregnancy loss, preterm labour and transplant associated adverse outcomes.

Acknowledgments
We thank Dr Feng-Chun Yang (Indiana University School of Medicine) for advises on writing.

Author Contributions
Conceived and designed the experiments: ZXY ZBH ZCH. Performed the experiments: ZXY ZBH YRW YWW YY SCG LNL WYL JPL DDC WJD XCC GSZ TW. Analyzed the data: ZXY ZBH ZCH. Wrote the paper: ZXY ZBH LI ZCH.

References
1. Le Blanc K, Rasmusson I, Sundberg B, Goetherstrom C, Hassan M, et al. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439–1441.
2. Zappa E, Casaza S, Pedemonte E, Benvenuto F, Bonanni I, et al. (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106: 1755–1761.
3. Kolf CM, Cho E, Tsau RS (2007) Mesenchymal stromal cells: Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther 9: 204.
4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multipotent adult progenitor cells. Science 284: 143–147.
5. Zuk PA, Ziemniak Z, Huang J, Futrelt JW, et al. (2001) Multipotent adult progenitor cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7: 211–220.
6. Fukushi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, et al. (2004) Human placenta-derived cells have mesenchymal/stromal progenitor cell potential. Stem Cells 22: 649–650.
7. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, et al. (2006) Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoesis-supportive function and other potentials. Haematologica 91: 1017–1026.
8. Lee OK, Kuo TK, Chen WM, Lee KD, Haich SL, et al. (2004) Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103: 1669–1675.
9. Bieback K, Kern S, Kocaomer A, Ferlik K, Bugert P (2008) Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng 18: 71–76.
10. Chen K, Wang D, Du WT, Han ZB, Ren H, et al. (2010) Human umbilical cord mesenchymal stem cells HUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol 135: 446–450.
11. Haich JV, Fu YS, Chang SJ, Tsang YH, Wang HW (2010) Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton's jelly of umbilical cord. Stem Dev 19: 1895–1910.
12. Liu G, Zhang XQ, Wang H, Wang X, Meng CL, et al. (2009) Comparative proteomic analysis of mesenchymal stem cells derived from human bone marrow, umbilical cord, and placenta: implication in the migration. Proteomics 9: 20–30.
13. Liu M, Yang SG, Shi L, Du WT, Liu PX, et al. (2010) Mesenchymal stem cells from bone marrow show a stronger stimulating effect on megakaryocyte progenitor expansion than those from non-hematopoietic tissues. Platelets 21: 199–210.
14. Bernardos ME, Emous JA, Karpenko M, Nault AJ, Willemze R, et al. (2007) Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. Connect Tissue Res 48: 172–180.
15. Huang JH, Shinn SS, Seok OS, Lee HY, Woo SK, et al. (2009) Comparison of cytokine expression in mesenchymal stem cells from human placenta, cord blood, and bone marrow. J Korean Med Sci 24: 547–554.
16. Jansen BJ, Gilissen C, Roelofs H, Schaap-Oziemlak A, Veltman JA, et al. (2010) CD106 identifies a unique subpopulation of MSCs with powerful immunosuppressive activity, CD106+MSCs with Unique Immunomodulatory Properties.
17. Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stem cells. Blood 110: 3499–3506.
18. Kokovay E, Wang Y, Kusek G, Wurster R, Lederman P, et al. (2012) VCAM1 is Essential to Maintain the Structure of the SVZ Niche and Acts as an Entry Point for Progenitor Cells. Stem Cells Dev 19: 481–490.
19. Kwee L, Baldwin HS, Shen HM, Sewsart CL, Buck G, et al. (1995) Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development 121: 1993–2003.
20. Gurner GC, Davis V, Li H, McCoy MJ, Sharpe A, et al. (1995) Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in choriogonadal fusion and placentation. Genes Dev 9: 1–14.
21. Terrena P, Kalikouridis M, Betz AG, Rahimović GA, Sano S, et al. (2007) Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am J Reprod Immunol 58: 238–254.
22. Trosedal J, Betz AG (2006) Mother’s little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 7: 241–246.
23. Alshihahi VR, Kalikouridis M, Betz AG (2004) Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 5: 266–271.
24. Galeria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, et al. (2005) A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 202: 231–237.
25. D’Addio F, Rieua LL, Mifarre BG, Chabtini L, Adams LT, et al. (2011) The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol 187: 4530–4541.
26. Vacchao MS, Hodes RJ (2003) Fetal expression of Fas ligand is necessary and sufficient for induction of CD8 T-cell tolerance to the fetal antigen H-Y during pregnancy. J Immunol 174: 4657–4661.
27. Wegmann TG, Liu H, Guillert M, Losmann TR (1993) Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 14: 335–336.
28. Mattsson R, Holmdahl R, Schyns A, Bernadotte F, Mattsson A, et al. (1991) Placental MHC class I antigen expression is induced in mice following in vivo treatment with recombinant interferon-gamma. J Reprod Immunol 19: 115–129.
29. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, et al. (2004) Human bone marrow stromal cells inhibit allologenic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103: 4616–4621.
30. Nemeth K, Keanne-Myers A, Brown JM, Metcalf DE, Graham JD, et al. (2010) Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci U S A 107: 5652–5657.
31. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. Blood 99: 3838–3843.
32. Nault AJ, Kruisselbrink AB, Larvink E, Willemze R, Fibbe WE (2006) Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 177: 2080–2087.
33. Selmani Z, Naji A, Gaiffe E, Obert L, Tiberghien P, et al. (2009) HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 87: 862–66.
34. Ren G, Zhang L, Zhao X, Xiu G, Zhang Y, et al. (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141–150.
35. Gieseke F, Boehringer J, Bussolari R, Dominici M, Handgretinger R, et al. (2010) Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effectors cells. Blood 116: 3730–3739.
36. Braun D, Longman RS, Albert ML (2005) A two-step induction of indoleamine 2,3-dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106: 2373–2381.
37. Cesario A, Rocca B, Rutella S (2011) The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX-2) in chronic inflammation and cancer. Carr Med Chem 18: 2263–2271.
40. Lim H, Paria BC, Das SK, Dinchak JE, Langenbach R, et al. (1997) Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91: 197–208.
41. Simon C, Valbuena D, Krussel J, Bernal A, Murphy CR, et al. (1998) Interleukin-1 receptor antagonist prevents embryonic implantation by a direct effect on the endometrial epithelium. Fertil Steril 70: 896–906.
42. Robin C, Bollerot K, Mendes S, Haak E, Crisan M, et al. (2009) Human placenta is a potent hematopoietic niche containing hematopoietic stem and progenitor cells throughout development. Cell Stem Cell 5: 385–395.
43. Wang D, Chen K, Du WT, Han ZB, Ren H, et al. (2010) CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells. Exp Cell Res 316: 2414–2423.
44. Polchert D, Sohinsky J, Douglas G, Kidd M, Moadsiri A, et al. (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38: 1745–1755.
45. English K, Barry FP, Field-Corbett CP, Mahon BP (2007) IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 110: 91–100.
46. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandhan AB (2010) Proinflammatory cytokines, IFN gamma and TNF alpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 5: e9016.
47. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, et al. (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24: 386–398.
48. Paulesu L, Jastra S, Jetta F, Brizzi R, Bigliardi E (2008) Interleukin-1 in reproductive strategies. Evol Dev 10: 778–788.
49. Terranova PF, Hunter VJ, RobyKF, Hunt JS (1995) Tumor necrosis factor-alpha in the female reproductive tract. Proc Soc Exp Biol Med 209: 325–342.